HeartBeam (BEAT)
(Delayed Data from NSDQ)
$2.36 USD
-0.05 (-2.07%)
Updated Nov 12, 2024 04:00 PM ET
After-Market: $2.35 -0.01 (-0.42%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.36 USD
-0.05 (-2.07%)
Updated Nov 12, 2024 04:00 PM ET
After-Market: $2.35 -0.01 (-0.42%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
BioTelemetry (BEAT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
BioTelemetry (BEAT) closed the most recent trading day at $67.54, moving -1.03% from the previous trading session.
Encouraging Near-Term Outlook for Medical Services Industry
by Urmimala Biswas
With growing importance of effective healthcare management, the medical service industry is becoming an integral part of the modern healthcare mechanism.
CareDx (CDNA) in Focus: Stock Moves 9.8% Higher
by Zacks Equity Research
CareDx (CDNA) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
The Zacks Analyst Blog Highlights: First Western, CBIZ, BioTelemetry, Expeditors International and Core-Mark
by Zacks Equity Research
The Zacks Analyst Blog Highlights: First Western, CBIZ, BioTelemetry, Expeditors International and Core-Mark
Zacks Market Edge Highlights: Tesla, BioTelemetary, Amazon, Booking and Nike
by Zacks Equity Research
Zacks Market Edge Highlights: Tesla, BioTelemetary, Amazon, Booking and Nike
Investing in the Innovation Winners
by Tracey Ryniec
If only an investor could buy companies that were on the cutting edge. How do you find those stocks?
U.S. Service Sector Humming: 5 Solid Buys
by Tirthankar Chakraborty
The non-manufacturing index comes in at 59.7 in February, topping analysts' estimates of 57.3. It also sees uninterrupted expansion for the 109th consecutive month.
BioTelemetry (BEAT) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
BioTelemetry (BEAT) delivered earnings and revenue surprises of 33.33% and 0.57%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
BioTelemetry (BEAT) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
BioTelemetry (BEAT) closed at $76.01 in the latest trading session, marking a -0.38% move from the prior day.
BioTelemetry (BEAT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
BioTelemetry (BEAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioTelemetry (BEAT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, BioTelemetry (BEAT) closed at $73.52, marking a +0.05% move from the previous day.
BioTelemetry (BEAT) Upgraded to Buy: Here's Why
by Zacks Equity Research
BioTelemetry (BEAT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
BioTelemetry (BEAT) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
BioTelemetry (BEAT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
BioTelemetry (BEAT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
BioTelemetry (BEAT) closed at $72.34 in the latest trading session, marking a +0.72% move from the prior day.
ResMed (RMD) Q2 Earnings in Line, Revenues Miss Estimates
by Zacks Equity Research
ResMed (RMD) benefits from growth at CER across all geographies. However, device sales in France and Japan get affected.
NextGen's (NXGN) Q3 Earnings Beat Estimates, Bookings Up Y/Y
by Zacks Equity Research
NextGen (NXGN) delivers strong growth in software, hardware and other non-recurring revenues in Q3; strong fiscal 2019 view buoys optimism.
Varian (VAR) Meets Q1 Earnings Estimates, Grows Globally
by Zacks Equity Research
Solid overseas growth boosts Varian's (VAR) fiscal Q1 results.
PetMed (PETS) Q3 Earnings Fall Y/Y, Reorder Sales Strong
by Zacks Equity Research
PetMed (PETS) sees reorder sales growth in Q3. Rising competition forced the company to offer additional discounts to customers in the quarter which had a negative impact on the gross margin.
Abbott (ABT) Q4 Earnings Meet Estimates, Organic Growth Solid
by Zacks Equity Research
Within Structural Heart, growth is driven by several product areas across Abbott's (ABT) broad portfolio.
BioTelemetry (BEAT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, BioTelemetry (BEAT) closed at $67.50, marking a +0.42% move from the previous day.
Top Ranked Momentum Stocks to Buy for January 23rd
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, January 23rd:
Teladoc Expands Services with Virtual Back Pain Treatment
by Zacks Equity Research
Teladoc's (TDOC) new addition of virtual back pain treatment will broaden its suite of products and services.
BioTelemetry (BEAT) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does BioTelemetry (BEAT) have what it takes to be a top stock pick for momentum investors? Let's find out.
BioTelemetry (BEAT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
BioTelemetry (BEAT) closed the most recent trading day at $68.16, moving -1.91% from the previous trading session.
Is BioTelemetry (BEAT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (BEAT) Outperforming Other Medical Stocks This Year?